{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:45:55Z","timestamp":1785901555930,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032702","name":"Genmab","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.molimm.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:44:34Z","timestamp":1781304274000},"page":"82-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["C1q-targeting bispecific antibodies bypass Fc to trigger complement activation and receptor clustering agonism"],"prefix":"10.1016","volume":"196","author":[{"given":"Douwe J.","family":"Dijkstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marfa I.","family":"Blanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"van der Meijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick J.","family":"Groenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bleijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Beurskens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leendert A.","family":"Trouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2026.06.006_bib1","doi-asserted-by":"crossref","first-page":"13455","DOI":"10.1021\/jacs.4c02772","article-title":"DNA Nanostructure-Templated Antibody Complexes Provide Insights into the Geometric Requirements of Human Complement Cascade Activation","volume":"146","author":"Abendstein","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.molimm.2026.06.006_bib2","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1038\/s41598-019-48461-1","article-title":"'A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells'","volume":"9","author":"Cruz","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2026.06.006_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4049\/jimmunol.177.2.1129","article-title":"'Modulation of the effector functions of a human IgG1 through engineering of its hinge region'","volume":"177","author":"Dall'Acqua","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002344","article-title":"A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface","volume":"14","author":"de Jong","year":"2016","journal-title":"PLoS. Biol."},{"key":"10.1016\/j.molimm.2026.06.006_bib5","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.1073\/pnas.1406849111","article-title":"Complement activation by ligand-driven juxtaposition of discrete pattern recognition complexes","volume":"111","author":"Degn","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molimm.2026.06.006_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.molimm.2026.06.006_bib7","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310666120","article-title":"'Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation'","volume":"120","author":"Dijkstra","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.molimm.2026.06.006_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406192121","article-title":"Complement activation by IgG subclasses is governed by their ability to oligomerize upon antigen binding","volume":"121","author":"Frischauf","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molimm.2026.06.006_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.molimm.2026.06.006_bib10","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.166.4.2571","article-title":"'Engineered antibodies with increased activity to recruit complement'","volume":"166","author":"Idusogie","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nbt0797-629","article-title":"Complement recruitment using bispecific diabodies","volume":"15","author":"Kontermann","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molimm.2026.06.006_bib12","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1038\/nprot.2014.169","article-title":"Controlled Fab-arm exchange for the generation of stable bispecific IgG1","volume":"9","author":"Labrijn","year":"2014","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.molimm.2026.06.006_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4161\/mabs.2.2.11158","article-title":"Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions","volume":"2","author":"Moore","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.molimm.2026.06.006_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2016.00079","article-title":"Structural and Functional Characterization of a Single-Chain Form of the Recognition Domain of Complement Protein C1q","volume":"7","author":"Moreau","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1073\/pnas.1616998114","article-title":"Structure and activation of C1, the complex initiating the classical pathway of the complement cascade","volume":"114","author":"Mortensen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.molimm.2026.06.006_bib16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.molimm.2026.06.006_bib17","article-title":"Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches","volume":"77","author":"Ovcinnikovs","year":"2024","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib18","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1535-7163.MCT-20-0044","article-title":"Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism","volume":"19","author":"Overdijk","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.molimm.2026.06.006_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4049\/jimmunol.2200952","article-title":"Bispecific Complement Engagers for Targeted Complement Activation","volume":"211","author":"Pedersen","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib20","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216422","article-title":"'Nanobody-mediated complement activation to kill HIV-infected cells'","volume":"15","author":"Pedersen","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.molimm.2026.06.006_bib21","series-title":"Method for detecting immune complexes in serum","article-title":"In, edited by US Patent & Trademark Office","author":"Reckel","year":"1986"},{"key":"10.1016\/j.molimm.2026.06.006_bib22","series-title":"US Patent & Trademark Office. United States: Annexon, Inc","article-title":"\"Anti-complement factor C1q antibodies and uses thereof.\"","author":"Rosenthal","year":"2019"},{"key":"10.1016\/j.molimm.2026.06.006_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"'Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions'","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.molimm.2026.06.006_bib24","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acs.nanolett.9b02220","article-title":"'Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces'","volume":"19","author":"Strasser","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.molimm.2026.06.006_bib25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1172\/JCI200421075","article-title":"Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes","volume":"114","author":"Trouw","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molimm.2026.06.006_bib26","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.aao4988","article-title":"Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement","volume":"359","author":"Ugurlar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.molimm.2026.06.006_bib27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.molimm.2021.10.010","article-title":"Circulating C1q levels in health and disease, more than just a biomarker","volume":"140","author":"van de Bovenkamp","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2026.06.006_bib28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2026.06.006_bib29","doi-asserted-by":"crossref","first-page":"27134","DOI":"10.1074\/jbc.M116.757773","article-title":"Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody","volume":"291","author":"Zhang","year":"2016","journal-title":"J. Biol. Chem."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902600146X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902600146X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:00:07Z","timestamp":1785898807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016158902600146X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"alternative-id":["S016158902600146X"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.06.006","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C1q-targeting bispecific antibodies bypass Fc to trigger complement activation and receptor clustering agonism","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}